{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:01:51Z","timestamp":1790298111065,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI068619"],"award-info":[{"award-number":["UM1AI068619"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["UM1AI068617"],"award-info":[{"award-number":["UM1AI068617"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UM1AI068613"],"award-info":[{"award-number":["UM1AI068613"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Opioid agonist treatment (OAT) is an effective method of addiction treatment and HIV prevention. However, globally, people who inject drugs (PWID) have insufficient OAT uptake. To expand OAT access and uptake, policymakers, program developers and healthcare providers should be aware of barriers to and facilitators of OAT uptake among PWID.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>As a part of the HPTN 074 study, which assessed the feasibility of an intervention to facilitate HIV treatment and OAT in PWID living with HIV in Indonesia, Ukraine, and Vietnam, we conducted in-depth interviews with 37 HIV-positive PWID and 25 healthcare providers to explore barriers to and facilitators of OAT uptake. All interviews were audio-recorded, transcribed, translated into English, and coded in NVivo for analysis. We developed matrices to identify emergent themes and patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Despite some reported country-specific factors, PWID and healthcare providers at all geographic locations reported similar barriers to OAT initiation, such as complicated procedures to initiate OAT, problematic clinic access, lack of information on OAT, misconceptions about methadone, financial burden, and stigma toward PWID. However, while PWID reported fear of drug interaction (OAT and antiretroviral therapy), providers perceived that PWID prioritized drug use over caring for their health and hence were less motivated to take up ART and OAT. Motivation for a life change and social support were reported to be facilitators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These results highlight a need for support for PWID to initiate and retain in drug treatment. To expand OAT in all three countries, it is necessary to facilitate access and ensure low-threshold, financially affordable OAT programs for PWID, accompanied with supporting interventions. PWID attitudes and beliefs about OAT indicate the need for informational campaigns to counter misinformation and stigma associated with addiction and OAT (especially methadone).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-020-00415-x","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T01:09:07Z","timestamp":1601514547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Perspectives of clients and providers on factors influencing opioid agonist treatment uptake among HIV-positive people who use drugs in Indonesia, Ukraine, and Vietnam: HPTN 074 study"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8480-6591","authenticated-orcid":false,"given":"Tetiana","family":"Kiriazova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian F.","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca B.","family":"Hershow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica L.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riza","family":"Sarasvita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Lancaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostyantyn","family":"Dumchev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irving F.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl A.","family":"Latkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,1]]},"reference":[{"issue":"1","key":"415_CR1","doi-asserted-by":"publisher","first-page":"204","DOI":"10.4081\/jphr.2014.204","volume":"3","author":"G Reid","year":"2014","unstructured":"Reid G, Sharma M, Higgs P. The long winding road of opioid substitution therapy implementation in South East Asia: challenges to scale up. J Public Health Res. 2014;3(1):204. https:\/\/doi.org\/10.4081\/jphr.2014.204.","journal-title":"J Public Health Res"},{"key":"415_CR2","unstructured":"UNAIDS. The Gap Report: Joint United Nations Programme on HIV\/AIDS, 2014.https:\/\/files.unaids.org\/en\/media\/unaids\/contentassets\/documents\/unaidspublication\/2014\/UNAIDS_Gap_report_en.pdf. Accessed 02 July 2020."},{"issue":"7","key":"415_CR3","first-page":"656","volume":"169","author":"E Wood","year":"2003","unstructured":"Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, O\u2019Shaughnessy MV, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ. 2003;169(7):656\u201361.","journal-title":"CMAJ"},{"issue":"1","key":"415_CR4","first-page":"46","volume":"35","author":"RD Moore","year":"2004","unstructured":"Moore RD, Keruly JC, Chaisson RE. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. JAIDS. 2004;35(1):46\u201351.","journal-title":"JAIDS"},{"issue":"4","key":"415_CR5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.drugpo.2012.09.005","volume":"24","author":"J De Maeyer","year":"2013","unstructured":"De Maeyer J, van Nieuwenhuizen C, Bongers IL, Broekaert E, Vanderplasschen W. Profiles of quality of life in opiate-dependent individuals after starting methadone treatment: a latent class analysis. Int J Drug Policy. 2013;24(4):342\u201350.","journal-title":"Int J Drug Policy"},{"key":"415_CR6","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/j.drugpo.2013.07.007","volume":"24","author":"BX Tran","year":"2013","unstructured":"Tran BX, Nguyen L. Impact of methadone maintenance on health utility, health care utilization and expenditure in drug users with HIV\/AIDS. Int J Drug Policy. 2013;24:e105\u201310.","journal-title":"Int J Drug Policy"},{"issue":"9","key":"415_CR7","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1111\/j.1360-0443.2008.02249.x","volume":"103","author":"P Lawrinson","year":"2008","unstructured":"Lawrinson P, Ali R, Buavirat A, Chiamwongpaet S, Dvoryak S, Habrat B, et al. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV\/AIDS. Addiction. 2008;103(9):1484\u201392.","journal-title":"Addiction"},{"issue":"3","key":"415_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/2046-4053-3-105","volume":"19","author":"BB Dennis","year":"2014","unstructured":"Dennis BB, Naji L, Bawor M, Bonner A, Varenbut M, Daiter J, et al. The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol. Syst Rev. 2014;19(3):105. https:\/\/doi.org\/10.1186\/2046-4053-3-105.","journal-title":"Syst. Rev."},{"key":"415_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.drugpo.2017.05.014","volume":"48","author":"K Dumchev","year":"2017","unstructured":"Dumchev K, Dvoryak S, Chernova O, Morozova O, Altice FL. Retention in medication-assisted treatment programs in Ukraine\u2014identifying factors contributing to a continuing HIV epidemic. Int J Drug Policy. 2017;48:44\u201353.","journal-title":"Int J Drug Policy"},{"key":"415_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.drugalcdep.2016.05.018","volume":"165","author":"LI Gardner","year":"2016","unstructured":"Gardner LI, Marks G, Strathdee SA, Loughlin AM, Del Rio C, Kerndt P, et al. Faster entry into HIV care among HIV-infected drug users who had been in drug-use treatment programs. Drug Alcohol Depend. 2016;165:15\u201321.","journal-title":"Drug Alcohol Depend"},{"key":"415_CR11","doi-asserted-by":"publisher","unstructured":"Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, et al; BHIVES Collaborative. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine\/naloxone treatment within HIV clinical care settings: results from a multisite study. JAIDS. 2011; 56(Suppl 1):S22\u201332. doi:https:\/\/doi.org\/10.1097\/QAI.0b013e318209751e","DOI":"10.1097\/QAI.0b013e318209751e"},{"key":"415_CR12","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s10461-008-9489-7","volume":"14","author":"M Malta","year":"2010","unstructured":"Malta M, Magnanini MM, Strathdee SA, Bastos FI. Adherence to antiretro-viral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav. 2010;14:731\u201347.","journal-title":"AIDS Behav"},{"issue":"8","key":"415_CR13","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1093\/cid\/ciw416","volume":"63","author":"AJ Low","year":"2016","unstructured":"Low AJ, Mburu G, Welton NJ, May MT, Davies CF, French C, et al. Impact of opioid substitution therapy on antiretroviral therapy outcomes: a systeOATic review and meta-analysis. Clin Infect Dis. 2016;63(8):1094\u2013104.","journal-title":"Clin Infect Dis"},{"key":"415_CR14","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s10461-013-0584-z","volume":"18","author":"H Reddon","year":"2014","unstructured":"Reddon H, Milloy M-J, Simo A, Montaner J, Wood E, Kerr T. Methadone maintenance therapy decreases the rate of antiretroviral therapy discontinuation among HIV-positive illicit drug users. AIDS Behav. 2014;18:740\u20136.","journal-title":"AIDS Behav"},{"issue":"9","key":"415_CR15","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1086\/630209","volume":"49","author":"P Roux","year":"2009","unstructured":"Roux P, Carrieri MP, Cohen J, Ravaux I, Poizot-Martin I, Dellamonica P, Spire B. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Infect Dis. 2009;49(9):1433\u201340.","journal-title":"Clin Infect Dis"},{"key":"415_CR16","unstructured":"Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations\u20142016 update. World Health Organization 2016. https:\/\/www.who.int\/hiv\/pub\/guidelines\/keypopulations-2016\/en\/. Accessed 30 Aug 2020."},{"issue":"12","key":"415_CR17","doi-asserted-by":"publisher","first-page":"e1208","DOI":"10.1016\/S2214-109X(17)30373-X","volume":"5","author":"S Larney","year":"2017","unstructured":"Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health. 2017;5(12):e1208\u201320.","journal-title":"Lancet Glob Health"},{"issue":"12","key":"415_CR18","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192\u2013207.","journal-title":"Lancet Glob Health"},{"issue":"3","key":"415_CR19","first-page":"255","volume":"22","author":"MJ Bojko","year":"2015","unstructured":"Bojko MJ, Mazhnaya A, Makarenko I, Marcus R, Dvoriak S, Islam Z, et al. \u201cBureaucracy & beliefs\u201d: assessing the barriers to accessing opioid substitution therapy by people who inject drugs in Ukraine. Drugs (Abingdon Engl). 2015;22(3):255\u201362.","journal-title":"Drugs (Abingdon Engl)"},{"key":"415_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jsat.2016.03.003","volume":"66","author":"MJ Bojko","year":"2016","unstructured":"Bojko MJ, Mazhnaya A, Marcus R, Makarenko I, Fillipovich S, Islam Z, et al. The future of opioid agonist therapies in Ukraine: a qualitative assessment of multilevel barriers and ways forward to promote retention in treatment. J Subst Abuse Treat. 2016;66:37\u201347.","journal-title":"J Subst Abuse Treat"},{"key":"415_CR21","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.3109\/10826084.2011.561905","volume":"46","author":"C Lin","year":"2011","unstructured":"Lin C, Wu Z, Detels R. Opiate users\u2019 perceived barriers against attending methadone maintenance therapy: a qualitative study in China. Subst Use Misuse. 2011;46:1190\u20138.","journal-title":"Subst Use Misuse"},{"issue":"9738","key":"415_CR22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0140-6736(10)60832-X","volume":"376","author":"D Wolfe","year":"2010","unstructured":"Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010;376(9738):355\u201366.","journal-title":"Lancet"},{"issue":"16","key":"415_CR23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12889-016-2897-0","volume":"8","author":"BX Tran","year":"2016","unstructured":"Tran BX, Vu PB, Nguyen LH, Latkin SK, Nguyen CT, Phan HTT, et al. Drug addiction stigma in relation to methadone maintenance treatment by different service delivery models in Vietnam. BMC Public Health. 2016;8(16):238. https:\/\/doi.org\/10.1186\/s12889-016-2897-0.","journal-title":"BMC Public Health"},{"issue":"1","key":"415_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-016-0127-9","volume":"14","author":"H Van Nguyen","year":"2017","unstructured":"Van Nguyen H, Nguyen HL, Mai HT, Le HQ, Tran BX, Hoang CD, et al. Stigmatization among methadone maintenance treatment patients in mountainous areas in northern Vietnam. Harm Reduct J. 2017;14(1):1. https:\/\/doi.org\/10.1186\/s12954-016-0127-9.","journal-title":"Harm Reduct J"},{"key":"415_CR25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.drugalcdep.2016.06.011","volume":"165","author":"I Makarenko","year":"2016","unstructured":"Makarenko I, Mazhnaya A, Polonsky M, Marcus R, Bojko MJ, Filippovych S, et al. Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine. Drug Alcohol Depend. 2016;165:213\u201320.","journal-title":"Drug Alcohol Depend"},{"key":"415_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12954-015-0063-0","volume":"12","author":"BX Tran","year":"2015","unstructured":"Tran BX, Nguyen LH, Phan HT, Nguyen LK, Latkin CA. Preference of methadone maintenance patients for the integrative and decentralized service delivery models in Vietnam. Harm Reduct J. 2015;12:29.","journal-title":"Harm Reduct J"},{"issue":"1","key":"415_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.5055\/jom.2006.0006","volume":"2","author":"C Callon","year":"2006","unstructured":"Callon C, Wood E, Marsh D, Li K, Montaner J, Kerr T. Barriers and facilitators to methadone maintenance therapy use among illicit opiate injection drug users in Vancouver. J Opioid Manag. 2006;2(1):35\u201341.","journal-title":"J Opioid Manag"},{"issue":"3","key":"415_CR28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jsat.2011.07.009","volume":"42","author":"R Sarasvita","year":"2012","unstructured":"Sarasvita R, Tonkin A, Utomo B, Ali R. Predictive factors for treatment retention in methadone programs in Indonesia. J Subst Abuse Treat. 2012;42(3):239\u201346.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"415_CR29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/QCO.0000000000000125","volume":"28","author":"A Kamarulzaman","year":"2015","unstructured":"Kamarulzaman A, Altice FL. Challenges in managing HIV in people who use drugs. Curr Opin Infect Dis. 2015;28(1):10\u20136.","journal-title":"Curr Opin Infect Dis"},{"issue":"10149","key":"415_CR30","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(18)31487-9","volume":"392","author":"WC Miller","year":"2018","unstructured":"Miller WC, Hoffman IF, Hanscom BS, Ha TV, Dumchev K, Djoerban Z, et al. A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomized, controlled phase 3 feasibility and efficacy study. Lancet. 2018;392(10149):747\u201359.","journal-title":"Lancet"},{"issue":"4","key":"415_CR31","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1007\/s10461-018-2307-y","volume":"23","author":"VF Go","year":"2019","unstructured":"Go VF, Hershow RB, Kiriazova T, Sarasvita R, Bui Q, Latkin CA, et al. Client and provider perspectives on antiretroviral treatment uptake and adherence among people who inject drugs in Indonesia, Ukraine and Vietnam: HPTN 074. AIDS Behav. 2019;23(4):1084\u201393.","journal-title":"AIDS Behav."},{"issue":"2","key":"415_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1521\/aeap.2019.31.2.95","volume":"31","author":"KE Lancaster","year":"2019","unstructured":"Lancaster KE, Miller WC, Kiriazova T, Sarasvita R, Bui Q, Ha TV, et al. Designing an individually tailored multilevel intervention to increase engagement in HIV and substance use treatment among people who inject drugs with HIV: HPTN 074. AIDS Educ Prev. 2019;31(2):95\u2013110.","journal-title":"AIDS Educ Prev."},{"issue":"10","key":"415_CR33","first-page":"136","volume":"4","author":"W Wulansari","year":"2019","unstructured":"Wulansari W, Rahmaniati MM. Why is the number of patients of methadone maintenance therapy in Indonesia stagnant? Improvement of service KnE Life. Sciences. 2019;4(10):136\u201343.","journal-title":"Sciences"},{"key":"415_CR34","unstructured":"IDPC Briefing Paper Drug policy in Indonesia. Lai G, Asmin F, Birgin R, 2013. https:\/\/idpc.net\/publications\/2013\/01\/idpc-briefing-paper-drug-policy-in-indonesiaAccessed 30 Aug 2020."},{"issue":"Suppl 4","key":"415_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S2055-6640(20)31096-7","volume":"2","author":"F Wijayanti","year":"2016","unstructured":"Wijayanti F, Tarmizi SN, Tobing V, Nisa T, Akhtar M, Trihandini I, Djuwita R. From the millennium development goals to sustainable development goals: the response to the HIV epidemic in Indonesia: challenges and opportunities. J Virus Erad. 2016;2(Suppl 4):27\u201331.","journal-title":"J. Virus Erad"},{"key":"415_CR36","unstructured":"Public Health Center of the Ministry of Health of Ukraine. OST statistics. https:\/\/www.phc.org.ua\/kontrol-zakhvoryuvan\/zalezhnist-vid-psikhoaktivnikh-rechovin\/zamisna-pidtrimuvalna-terapiya-zpt\/statistika-zpt Accessed 02 July 2020."},{"key":"415_CR37","unstructured":"Ministry of Health of Ukraine (2016). Order of 17.12.2015 No 863 On amendments to the Order of the Ministry of Health of Ukraine of 27.03.2012 No 200 \u201cOn approval of the procedure of substitution maintenance therapy for patients with opioid dependence\u201d. (In Ukrainian)."},{"key":"415_CR38","unstructured":"HIV Infection in Ukraine. Informational Bulletin No 50. Public Health Center of the Ministry of Health of Ukraine, Kyiv, 2019. https:\/\/www.phc.org.ua\/sites\/default\/files\/users\/user90\/HIV_in_UA_50_2019_EN.pdf. Accessed 30 Aug 2020."},{"key":"415_CR39","unstructured":"Global State of Harm Reduction 2018. https:\/\/www.hri.global\/global-state-harm-reduction-2018. Accessed 30 Aug 2020."},{"key":"415_CR40","doi-asserted-by":"crossref","unstructured":"Le TA, Pham DTT, Quek TTC, Vu GT, Hoang CL, Tran TT, et al. Polysubstance Use among Patients Enrolling in Methadone Maintenance Treatment Program in a Vietnam Province with Drug-Driven HIV Epidemic. Int J Environ Res Public Health. 2019;16(18).","DOI":"10.3390\/ijerph16183277"},{"issue":"2","key":"415_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/23288604.2018.1440347","volume":"4","author":"B Johns","year":"2018","unstructured":"Johns B, Chau LB, Hanh KH, Manh PD, Do HM, Duong AT, Nguyen LH. Association between user fees and dropout from methadone maintenance therapy: results of a cohort study in Vietnam. Health Syst Reform. 2018;4(2):101\u201313.","journal-title":"Health Syst. Reform"},{"key":"415_CR42","unstructured":"Country Operational Plan Vietnam COP 2019. Strategic Direction Summary April 12, 2019. https:\/\/www.state.gov\/wp-content\/uploads\/2019\/09\/Vietnam_COP19-Strategic-Directional-Summary_public.pdf. Accessed 30 Aug 2020."},{"key":"415_CR43","first-page":"239","volume-title":"Matrix displays: some rules of thumb qualitative data analysis","author":"MB Miles","year":"1994","unstructured":"Miles MB, Huberman AM. Matrix displays: some rules of thumb qualitative data analysis. Thousand Oaks: Sage; 1994. p. 239\u201344."},{"key":"415_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.12.021","volume":"61","author":"G Kourounis","year":"2016","unstructured":"Kourounis G, Richards BD, Kyprianou E, Symeonidou E, Malliori MM, Samartzis L. Opioid substitution therapy: lowering the treatment thresholds. Drug Alcohol Depend. 2016;61:1\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"13","key":"415_CR45","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1177\/1049732317732307","volume":"27","author":"J Rozanova","year":"2017","unstructured":"Rozanova J, Marcus R, Taxman FS, Bojko MJ, Madden L, Farnum SO, et al. Why people who inject drugs voluntarily transition off methadone in Ukraine. Qual Health Res. 2017;27(13):2057\u201370.","journal-title":"Qual Health Res"},{"key":"415_CR46","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.drugpo.2019.03.026","volume":"68","author":"TT Nguyen","year":"2019","unstructured":"Nguyen TT, Luong AN, Nham TTT, Chauvin C, Feelemyer J, Nagot N, et al. Struggling to achieve a \u201cnormal life\u201d: a qualitative study of Vietnamese methadone patients. Int J Drug Policy. 2019;68:18\u201326.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"415_CR47","first-page":"288","volume":"79","author":"A Mazhnaya","year":"2018","unstructured":"Mazhnaya A, Marcus R, Bojko MJ, Zelenev A, Makarenko I, Pykalo I, et al. Opioid agonist treatment and improved outcomes at each stage of the HIV treatment cascade in people who inject drugs in Ukraine. JAIDS. 2018;79(3):288\u201395.","journal-title":"JAIDS"},{"issue":"1","key":"415_CR48","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12916-018-1246-9","volume":"17","author":"JM Turan","year":"2019","unstructured":"Turan JM, Elafros MA, Logie CH, Banik S, Turan B, Crockett KB, Pescosolido B, Murray SM. Challenges and opportunities in examining and addressing intersectional stigma and health. BMC Med. 2019;17(1):7.","journal-title":"BMC Med."},{"key":"415_CR49","doi-asserted-by":"crossref","unstructured":"Calabrese SK, Burke SE, Dovidio JF, Levina OS, Uuskula A, Niccolai LM, Heimer R. Internalized HIV and drug stigmas: interacting forces threatening health status and health service utilization among people with HIV who inject drugs in St. Petersburg, Russia. AIDS Behav. 2016;20(1):85\u201397.","DOI":"10.1007\/s10461-015-1100-4"},{"issue":"8","key":"415_CR50","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1177\/1359105313507964","volume":"20","author":"V Earnshaw","year":"2015","unstructured":"Earnshaw V, Smith L, Cunningham C, Copenhaver M. Intersectionality of internalized HIV stigma and internalized substance use stigma: implications for depressive symptoms. J Health Psychol. 2015;20(8):1083\u20139.","journal-title":"J Health Psychol."},{"key":"415_CR51","doi-asserted-by":"publisher","first-page":"108216","DOI":"10.1016\/j.drugalcdep.2020.108216","volume":"216","author":"A Meteliuk","year":"2020","unstructured":"Meteliuk A, Prokhorova T, Filippovych S, Ompad DC, Zaller N. The role of access to integrated services at opioid agonist treatment sites in reaching 90\u201390-90 cascade in people who inject drugs in Ukraine: Country-level data. Drug Alcohol Depend. 2020;216:108216.","journal-title":"Drug Alcohol Depend"},{"key":"415_CR52","doi-asserted-by":"publisher","first-page":"e25492","DOI":"10.1002\/jia2.25492","volume":"23","author":"Y Sereda","year":"2020","unstructured":"Sereda Y, Kiriazova T, Makarenko O, Carroll JJ, Rybak NR, Chybisov A, Bendiks S, Idrisov B, Dutta A, Gillani F, Samet JH, Lunze K. Stigma and quality of co-located care for HIV-positive people in addiction treatment in Ukraine: a cross-sectional study. JIAS. 2020;23:e25492.","journal-title":"JIAS"},{"key":"415_CR53","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.drugalcdep.2018.05.027","volume":"190","author":"A Zelenev","year":"2018","unstructured":"Zelenev A, Shea P, Mazhnaya A, Rozanova J, Madden L, Marcus R, et al. Assessment of barrier severity and willingness to enter opioid agonist treatment among people who inject drugs in Ukraine. Drug Alcohol Depend. 2018;190:82\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"4 Suppl 3","key":"415_CR54","doi-asserted-by":"publisher","first-page":"20897","DOI":"10.7448\/IAS.19.4.20897","volume":"19","author":"O Kutsa","year":"2016","unstructured":"Kutsa O, Marcus R, Bojko MJ, Zelenev A, Mazhnaya A, Dvoriak S, et al. Factors associated with physical and sexual violence by police among people who inject drugs in Ukraine: implications for retention on opioid agonist therapy. JIAS. 2016;19(4 Suppl 3):20897.","journal-title":"JIAS"},{"issue":"1","key":"415_CR55","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.drugalcdep.2013.05.018","volume":"133","author":"JM Izenberg","year":"2013","unstructured":"Izenberg JM, Bachireddy C, Soule M, Kiriazova T, Dvoryak S, Altice FL. High rates of police detention among recently released HIV-infected prisoners in Ukraine: implications for health outcomes. Drug Alcohol Depend. 2013;133(1):154\u201360.","journal-title":"Drug Alcohol Depend"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-020-00415-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-020-00415-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-020-00415-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T21:53:13Z","timestamp":1633038793000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-020-00415-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["415"],"URL":"https:\/\/doi.org\/10.1186\/s12954-020-00415-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-42695\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-42695\/v2","asserted-by":"object"}]},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]},"assertion":[{"value":"13 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol (available at\n                      \n                      ) was approved by the following institutional review boards: Institutional Review Board of Ukrainian Institute on Public Health Policy (Ukraine); Ethical Review Board for Biomedical Research Hanoi School of Public Health (Vietnam); Ethics Committee of Faculty of Medicine, University of Indonesia\/Cipto Mangunkusumo Hospital (Indonesia); and the University of North Carolina Institutional Review Board. All participants provided written informed consent to participate in the qualitative interview as a part of the HPTN 074 trial.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}